Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?
This article was originally published in The Pink Sheet Daily
After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.
You may also be interested in...
SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.